Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin A Rogers

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
BMJ Open|June 27, 2023
Non-inferiority trial of a shorter (7 days) compared with a longer (14 days) duration of antimicrobial therapy for the treatment of bacteraemic urinary sepsis, measured by microbiological success after the completion of therapy: a substudy protocol for the Bacteraemia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) multicentre randomised controlled trialBenjamin A Rogers, Robert Fowler, Patrick N A Harris, et al.
Journal of Personality and Social Psychology|March 27, 2023
Seeing your life story as a Hero's Journey increases meaning in lifeBenjamin A Rogers, Herrison Chicas, John Michael Kelly, et al.
International Journal of Antimicrobial Agents|February 25, 2015
Sequence type 131 fimH30 and fimH41 subclones amongst Escherichia coli isolates in Australia and New ZealandBenjamin A Rogers, Paul R Ingram, Naomi Runnegar, et al.
Trials|October 14, 2020
An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trialJames H McMahon, Jillian S Y Lau, Janine Roney, et al.
The Medical Journal of Australia|May 19, 2010
Disproportionate impact of pandemic (H1N1) 2009 influenza on Indigenous people in the Top End of Australia's Northern TerritoryShaun M Flint, Joshua S Davis, Jiunn-Yih Su, et al.
BMJ Open|July 2, 2026
Towards use of Patient-informed Relevant Outcomes (PRO) in trials of bloodstream infections: a mixed-methods study protocol (BALANCE+PRO)Ranjani Somayaji, Victoria Haldane, Rob Fowler, et al.
Antimicrobial Agents and Chemotherapy|January 29, 2014
Community-onset Escherichia coli infection resistant to expanded-spectrum cephalosporins in low-prevalence countriesBenjamin A Rogers, Paul R Ingram, Naomi Runnegar, et al.
International Journal of Antimicrobial Agents|August 3, 2020
Identification and characterisation of fosfomycin resistance in Escherichia coli urinary tract infection isolates from AustraliaShakeel Mowlaboccus, Denise Daley, Stanley Pang, et al.
Trials|January 28, 2015
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trialPatrick N A Harris, Anton Y Peleg, Jon Iredell, et al.
Trials|January 17, 2020
A pilot randomized controlled trial of 7 versus 14 days of antibiotic treatment for bloodstream infection on non-intensive care versus intensive care wardsNick Daneman, Asgar H Rishu, Ruxandra Pinto, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
BMJ Open|June 27, 2023
Non-inferiority trial of a shorter (7 days) compared with a longer (14 days) duration of antimicrobial therapy for the treatment of bacteraemic urinary sepsis, measured by microbiological success after the completion of therapy: a substudy protocol for the Bacteraemia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) multicentre randomised controlled trialBenjamin A Rogers, Robert Fowler, Patrick N A Harris, et al.
Journal of Personality and Social Psychology|March 27, 2023
Seeing your life story as a Hero's Journey increases meaning in lifeBenjamin A Rogers, Herrison Chicas, John Michael Kelly, et al.
International Journal of Antimicrobial Agents|February 25, 2015
Sequence type 131 fimH30 and fimH41 subclones amongst Escherichia coli isolates in Australia and New ZealandBenjamin A Rogers, Paul R Ingram, Naomi Runnegar, et al.
Trials|October 14, 2020
An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trialJames H McMahon, Jillian S Y Lau, Janine Roney, et al.
The Medical Journal of Australia|May 19, 2010
Disproportionate impact of pandemic (H1N1) 2009 influenza on Indigenous people in the Top End of Australia's Northern TerritoryShaun M Flint, Joshua S Davis, Jiunn-Yih Su, et al.
BMJ Open|July 2, 2026
Towards use of Patient-informed Relevant Outcomes (PRO) in trials of bloodstream infections: a mixed-methods study protocol (BALANCE+PRO)Ranjani Somayaji, Victoria Haldane, Rob Fowler, et al.
Antimicrobial Agents and Chemotherapy|January 29, 2014
Community-onset Escherichia coli infection resistant to expanded-spectrum cephalosporins in low-prevalence countriesBenjamin A Rogers, Paul R Ingram, Naomi Runnegar, et al.
International Journal of Antimicrobial Agents|August 3, 2020
Identification and characterisation of fosfomycin resistance in Escherichia coli urinary tract infection isolates from AustraliaShakeel Mowlaboccus, Denise Daley, Stanley Pang, et al.
Trials|January 28, 2015
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trialPatrick N A Harris, Anton Y Peleg, Jon Iredell, et al.
Trials|January 17, 2020
A pilot randomized controlled trial of 7 versus 14 days of antibiotic treatment for bloodstream infection on non-intensive care versus intensive care wardsNick Daneman, Asgar H Rishu, Ruxandra Pinto, et al.
Pageof 6